LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial

Autor:	Elsa Kalbacher, Ulrich Canzler, N. Dohollou, Claudio Zamagni, Frederik Marmé, C. Costan, P. Gargiulo, A. González Martín, J. Maenpaa, Alessandra Bologna, Youssef Tazi, K. Yonemori, Ignace Vergote, I.L. Ray-Coquard, N de Gregorio, E.M. Guerra-Alia, L. Montane, Florian Heitz, C.B. Levaché, R. Berger
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Bevacizumab business.industry Hematology Newly diagnosed Olaparib chemistry.chemical_compound chemistry Internal medicine Ovarian carcinoma medicine In patient Progression-free survival business medicine.drug
Zdroj:	Annals of Oncology. 31:S1163-S1164
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.2263
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e85a5d6e6abf5310ff78d8ff800a9160 https://doi.org/10.1016/j.annonc.2020.08.2263 Zobrazit plný text záznamu